Dec. 6, 2005 — Allozyne Inc., based in Seattle, has raised approximately $3.5 million in Series A funding. The investors include MPM Capital, Arch Venture Partners, and OVP Venture Partners.
Mitchell Bloom, James Kasinger and James Burns represented the investors in this transaction.
Related Content
- Big Molecule WatchDecember 9, 2024
Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025
- Big Molecule WatchDecember 7, 2024
Biocon Announces FDA Approval of Ustekinumab Biosimilar
- Big Molecule WatchDecember 4, 2024
Update on Pending Denosumab BPCIA Litigations
- AlertDecember 4, 2024
Preliminary Injunction Halts Corporate Transparency Act Enforcement: What You Need to Know
- Big Molecule WatchNovember 27, 2024
European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar
- Big Molecule WatchNovember 19, 2024
FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- AlertNovember 19, 2024
Corporate Transparency Act: January 1 Deadline is Almost Here
- Big Molecule WatchNovember 18, 2024
Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar
- WebinarJanuary 13, 2025
Goodwin CLE Week 2025
- Press ReleaseDecember 10, 2024
AQEMIA Raises $38 Million
- Press ReleaseDecember 6, 2024
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Press ReleaseDecember 6, 2024
Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics’ PEG Supply Business and Manufacturing Facility
- Press ReleaseDecember 6, 2024
Destination Life Sciences M&A: Goodwin’s Q3 Momentum
- Press ReleaseDecember 5, 2024
Goodwin Advised Nuvig Therapeutics on $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
- Press ReleaseDecember 3, 2024
Goodwin Advises Tubulis on Exclusive Option and License Agreement with Gilead to Develop ADC Candidate for Select Solid Tumor Target for $20 Million Upfront and up to $445 Million in Additional Payments
- Press ReleaseDecember 3, 2024
Goodwin Advises Relay Therapeutics in Exclusive Global License Agreement with Elevar Therapeutics for up to $75 Million Upfront and in Regulatory Milestones and up to $425 Million in Commercial Milestones